tiprankstipranks
Advertisement
Advertisement

Niagen Bioscience sees FY26 revenue up 10%-15%, implying $142.3M-$148.8M

Consensus $152.9M. Sees FY26 gross margin with “slight improvement year-over-year, driven by improvements in inventory cost and product mix.”

Meet Samuel – Your Personal Investing Prophet

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1